Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Kuek A; Hazleman BL; Ostor AJPostgrad Med J 2007[Apr]; 83 (978): 251-60Targeted biologic therapies have revolutionised treatment of immune-mediated inflammatory diseases (IMIDs) due to their efficacy, speed of onset and tolerability. The discovery that clinically unrelated conditions, such as rheumatoid arthritis and Crohn's disease, share similar immune dysregulation has led to a shift in the management of IMIDs from one of organ-based symptom relief to mechanism-based treatment. The fact that anticytokine therapy has been effective in treating multiple orphan inflammatory conditions confirms the IMID paradigm. In this review we examine the biologic agents currently licensed for use in the US and Europe: infliximab, etanercept, adalimumab, rituximab, abatacept, anakinra, alefacept and efalizumab. We also discuss the rationale behind the management of IMIDs using rheumatoid arthritis, Crohn's disease, psoriasis and psoriatic arthritis as examples. For the medical profession, IMID represents a breakthrough in the way pathology is classified. In this burgeoning era of biologic therapy the prospect of complete disease remission is conceivable.|Abatacept[MESH]|Alefacept[MESH]|Anti-Inflammatory Agents/*therapeutic use[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal, Murine-Derived[MESH]|Antibodies, Monoclonal/therapeutic use[MESH]|Antirheumatic Agents/*therapeutic use[MESH]|Arthritis, Psoriatic/*drug therapy[MESH]|Arthritis, Rheumatoid/*drug therapy[MESH]|Certolizumab Pegol[MESH]|Crohn Disease/*drug therapy[MESH]|Dermatologic Agents/*therapeutic use[MESH]|Drug Costs[MESH]|Etanercept[MESH]|Humans[MESH]|Immunoconjugates/therapeutic use[MESH]|Immunoglobulin Fab Fragments/therapeutic use[MESH]|Immunoglobulin G/therapeutic use[MESH]|Infliximab[MESH]|Phenetidine/analogs & derivatives/therapeutic use[MESH]|Polyethylene Glycols/therapeutic use[MESH]|Receptors, Tumor Necrosis Factor/therapeutic use[MESH]|Recombinant Fusion Proteins/therapeutic use[MESH]|Rituximab[MESH] |